4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Frontage Holdings Corporation (1521) operates in the Biotechnology industry and is headquartered in Exton, United States with about 1,523 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, 1521 reported $257M in revenue and $7M in net income.
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $257M | $255M | $260M | $250M |
| Gross Profit | $69M | $70M | $78M | $89M |
| Operating Income (EBIT) | $20M | $9M | $20M | $35M |
| Net Income | $7M | $1M | $11M | $26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $541M | $554M | $572M | $551M | — |
| Total Liabilities | $193M | $219M | $227M | $215M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1521 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms